These innovative molecules represent a significant progression in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://rsadewj286484.blogofchange.com/39780857/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide